Company / SG&A Expense
Boston Scientific SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.9B
FY2025
5-year range
$3.9B / $6.9B
FY2021-FY2025
Trend
+15.1%
vs FY2024
Sector context
#12 of 158
Health Care
What the data says
Among 158 Health Care companies, Boston Scientific is in the bottom 8% for sg&a expense. SG&A Expense has increased for 5 consecutive years, from $3.6B in FY2020 to $6.9B in FY2025.
Based on SEC 10-K filings.
$6.9B in FY2025 with a 5-year CAGR of +14.1%. Top quartile in the Health Care sector.
Increased from $5.2B to $6.9B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.1%
- 5-Year CAGR
- +14.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 158This company $6.9B Sector average $175.9B
▼
-96.1% below sector average
Key checks
Key Insights
- Boston Scientific's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +14.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.1% year-over-year.
- Ranks #12 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.9B | +15.1% |
| FY2024 | $6.0B | +15.3% |
| FY2023 | $5.2B | +14.8% |
| FY2022 | $4.5B | +14.7% |
| FY2021 | $3.9B | +10.4% |
| FY2020 | $3.6B | -9.4% |
| FY2019 | $3.9B | +10.4% |
| FY2018 | $3.6B | +8.3% |
| FY2017 | $3.3B | +6.3% |
| FY2016 | $3.1B | +7.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026